Skip to main content
GeneOne Life Science, Inc. logo

GeneOne Life Science, Inc. — Investor Relations & Filings

Ticker · 011000 ISIN · KR7011000007 KO Professional, scientific and technical activities
Open in API
Filings indexed 490 across all filing types
Latest filing 2026-04-07 Regulatory Filings
Country KR South Korea
Listing KO 011000

About GeneOne Life Science, Inc.

https://www.genels.com/en/

GeneOne Life Science, Inc. is a biopharmaceutical research and development company specializing in nucleic acid-based biomedicines. The company's core focus is on developing DNA and mRNA vaccines, particularly for emerging infectious diseases, leveraging its rapid development platforms. In therapeutics, GeneOne utilizes a proprietary DNA plasmid delivery technology to enable the expression of recombinant proteins and plasmid-encoded monoclonal antibodies (Plas-mAbs®). This non-viral vector approach is designed to offer a safer and more cost-effective alternative to traditional gene therapies and cell-line derived monoclonal antibody treatments for conditions such as cancers and autoimmune disorders. The company also develops immunomodulatory small molecule drugs. Through its subsidiary, GeneOne possesses cGMP-grade manufacturing capabilities for DNA plasmids, supporting its internal pipeline and contract manufacturing services.

Recent filings

Filing Released Lang Actions
[기재정정]자본잠식50%이상또는매출액50억원미만사실발생
Regulatory Filings Classification · 85% confidence The document is a Korean stock exchange regulatory disclosure (“정정신고(보고)”) correcting previously announced financial thresholds (capital erosion over 50%, sales below 50bn KRW). It is not an AGM presentation, earnings release, or annual/interim report itself, nor a board change or M&A. It is a standard regulatory filing under Korean securities rules, serving as an amendment to an earlier announcement. This falls under the general “Regulatory Filings” category (RNS).
2026-04-07 Korean
[기재정정]타인에대한채무보증결정
Capital/Financing Update Classification · 85% confidence The document is a Korean public disclosure titled “타인에 대한 채무보증 결정” (Decision to guarantee another party’s debt) with corrected details on guarantee period and amounts. It is not a full financial report, nor AGM materials, dividend notice, or share issuance. It pertains to the company’s financing activity by providing guarantee on a subsidiary’s borrowing. This aligns with the Capital/Financing Update category (CAP).
2026-04-07 Korean
매출채권이외의채권에서발생한손상차손
Audit Report / Information Classification · 90% confidence The document details impairment losses on receivables other than trade receivables, including specific financial figures such as impairment loss amounts, equity capital, and detailed breakdowns of long-term loans and accrued income. It references the fiscal year-end 2025 financial statements and audit reports. The content is focused on financial data related to impairment losses and is not a brief announcement or a certification. The document length is short (1198 characters), but it contains substantive financial data and analysis related to impairment losses, which is typically part of an audit report or impairment disclosure. There is no indication that this is a full annual report or interim report, nor is it a simple announcement or certification. Given the focus on impairment losses and detailed financial figures, this fits best under Audit Report / Information (AR). FY 2025
2026-04-07 Korean
감사보고서제출
Audit Report / Information Classification · 93% confidence The document is titled “감사보고서 제출” (Audit Report Submission) and contains detailed auditor’s opinions, consolidated and standalone financial statement audit opinions, financial totals, and audit-related disclosures. It is not a brief notice or link-only announcement nor a full annual report, but the actual standalone audit report content. This aligns with the “Audit Report / Information” category (Code: AR). FY 2025
2026-04-07 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is titled as an "연결감사보고서" which translates to "Consolidated Audit Report". It includes an independent auditor's report, audit opinion, audit basis, key audit matters, and detailed consolidated financial statements for the fiscal years ending December 31, 2025 and 2024. The content includes auditor's responsibilities, management responsibilities, and detailed financial statements such as balance sheet, income statement, cash flow statement, and notes. The document is about 15,000 characters long and contains the full audit report and financial statements, not just an announcement or certification. Therefore, this document is a standalone audit report, not a full annual report or other filing type. Hence, the correct classification is Audit Report / Information (AR). FY 2025
2026-04-07 Korean
자본잠식50%이상또는매출액50억원미만사실발생
Earnings Release Classification · 85% confidence The document is a brief announcement in Korean of significant changes in financial performance and capital impairment exceeding 50%, with summary tables of revenue, profit, assets, liabilities, and equity for the current and prior year. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it simply announcing that a report is available (RPA). Instead, it presents key highlights of the year’s results and a material event (capital impairment and revenue drop). This matches the definition of an Earnings Release (ER) – an initial announcement of periodical financial results with key figures. FY 2025
2026-04-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.